PROSOLV® SMCC 50-A high-functional excipient from JRS Pharma

The development of coprocessed, multi-functional excipients has enabled formulators to address multiple challenges with a single excipient, resulting in enhanced production and better finished product quality.

Why PROSOLV® SMCC?

Attaining good hardness at low compaction forces is quite essential while considering suitability of excipient for tablet forMicrocrystalline mutation cellulose is one of the widely used and accepted excipients in tablet dosage form. Compactability of microcrystalline cellulose (MCC) is of prime importance during compression.PROSOLV SMCC is a novel high-functionality tableting excipient. The material is manufactured by co-processing MCC with colloidal silicon dioxide (CSD) and can be used to improve flow, lubricant sensitivity and tablet strength. The addition of CSD in MCC helps to improve compatibility

It has been reported that silicification appears to have no apparent effect on the primary chemical and polymorphic characteristics of MCC. This suggests that bulk modification of MCC does not occur during silicification and that the CSD, either by providing surface modification or by modifying strengthening interactions, is primarily responsible for the improvements in functionality, in particular tablet strength. This may be solely due to a morphological property or some other silicon dioxide MCC interfacial interaction. Based on scanning electron microscopy studies together with electron microprobe analysis, it was stated that silicon dioxide is primarily located at the surface of the SMCC particles. While certain amounts of silicon dioxide were detected in the internal regions of some particles, the colloidal silicon dioxide particles present at the surfaces of the SMCC particles are shown to be uniformly distributed24.